



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	09/724,288
--------------------	------------

Filing Date	November 28, 2000
-------------	-------------------

First Named Inventor	Schenk, Dale B.
----------------------	-----------------

Art Unit	1647
----------	------

Examiner Name	Sharon L. Turner
---------------	------------------

Attorney Docket Number	15270J-004765US
------------------------	-----------------

U.S. PATENT DOCUMENTS+

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	of	3	Application Number	09/724,288
-------	---	----	---	--------------------	------------

Complete if Known

Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Sharon L. Turner
Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	418	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <u>Genome Research</u> , 10:398-400 (2000)	
	419	BORK et al., "Go hunting in sequence databases but watch out for the traps," <u>Trends in Genetics</u> , 12(10):425-427 (1996).	
	420	BRENNER, S. E., "Errors in genome annotation," <u>Trends in Genetics</u> , 15(4):132-133 (1999).	
	421	CASTILLO et al., "Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology," <u>Diabete & Metabolisme (Paris)</u> , 21:3-25 (1995).	
	412	DAS et al., "Amyloid- β Immunization Effectively Reduces Amyloid Deposition in FcR γ Knock-Out-Mice," <u>J. Neuroscience</u> , 23(24):8532-8538 (2003)	
	436	DICKSON et al., "Neuroimmunology of Alzheimer's disease: a conference report," <u>Neurobiology of Aging</u> , 13(6):793-798 (1992), abstract only	
	422	DOERKS et al., "Protein annotation: detective work for function prediction," <u>Trends in Genetics</u> , 14(6):248-250 (1998).	
	407	ECK et al., <i>Goodman and Gilman's The pharmacological basis of therapeutics</i> , Chapter 5, pages 77-101 (1996)	
	423	FONSECA et al., "The Presence of Isoaspartic Acid in β -Amyloid Plaques Indicates Plaque Age," <u>Experimental Neurology</u> , 157(2):277-288 (1999).	
	424	GOLDSBY et al., "Vaccines," Chapter 18 from <i>Immunology</i> , 4th Edition, W.H. Freeman and Company, New York, pages 449-465. (2000)	
	413	HOLTZMAN et al., "A β immunization and anti-A β antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <u>Advanced Drug Delivery Reviews</u> , 54:1603-1613 (2002).	
	434	KELLY, J. W., "Alternative conformations of amyloidogenic proteins govern their behavior," <u>Current Opinion in Structural Biology</u> , 6:11-17 (1996).	
	408	MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995).	
	439	NALBANTOGLU, J., "Beta-amyloid protein in Alzheimer's disease," <u>Can. J. Neurol. Sci.</u> , 18(3 suppl.):424-427 (1991), abstract only	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Sheet <u>1</u> of <u>1</u> (use as many sheets as necessary)				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number 09/724,288	
(use as many sheets as necessary)				Filing Date November 28, 2000	
Sheet <u>3</u> of <u>3</u>				First Named Inventor Schenk, Dale B.	
				Art Unit 1647	
				Examiner Name Sharon L. Tumer	
				Attorney Docket Number 15270J-004765US	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	425	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pages 492-495 from Chapter 14 of <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz et al., eds., Birkhauser Boston (1994).		
	409	ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995		
	437	PERSSON et al., "IgG subclass-associated affinity differences of specific antibodies in humans," <u>J. Immunology</u> , 140(11):3875-3879 (1988), abstract only		
	414	SCHENK, D., "Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning," <u>Nature Reviews</u> , 3:824-828 (2002).		
	426	SINGH, K. S., "Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease," <u>Gerontology</u> , 43:79-94 (1997).		
	438	SINGH, V. K., "Studies of neuroimmune markers in Alzheimer's disease," <u>Mol. Neurobiology</u> , 9(1-3):73-81 (1994), abstract only		
	427	SMITH et al., "The challenges of genome sequence annotation or 'The devil is in the details,'" <u>Nature Biotechnology</u> , 15:1222-1223 (1997).		
	411	SOLOMON et al., "The Amino Terminus of the β -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility," from <i>Progress in Alzheimer's and Parkinson's Diseases</i> , edited by Fisher et al., Plenum Press, New York, pages 205-211 (1995).		
	435	STERN et al., "Antibodies to the β -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood," <u>FEBS Letters</u> , 264(1):43-47 (1990).		
	428	VELAZQUEZ et al., "Aspartate residue 7 in amyloid β -protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis," <u>Nature Medicine</u> , 3(1):77-79 (1997).		
	410	VERMA et al., "Gene therapy - promises, problems and prospects," <u>Nature</u> , 389:239-242 (1997).		
	429	WELLS, J. A., "Additivity of Mutational Effects in Proteins," <u>Biochemistry</u> , 29(37):8509-8517 (1990).		
	430	YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid β -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).		

Examiner Signature	/Daniel Kolker/	Date Considered	03/18/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.